Back to Insights
Industry March 23, 2026 · 37 min read

Korean Digital Healthcare Landscape

Korean Digital Healthcare Landscape

Key Takeaway

Korea's December 2025 telemedicine legalization marks a structural inflection point for the country's digital health market, projected to reach USD $1.3 billion in 2026. Canadian companies with established telemedicine platforms, remote patient monitoring devices, or chronic disease management solutions are well-positioned to capitalize on immediate procurement demand from Korean hospitals and clinics.

# Korean Digital Healthcare Landscape

South Korea is emerging as one of the world's leading digital health markets, driven by a convergence of factors that few other countries can match: a technology-savvy population with near-universal smartphone penetration, a world-class hospital system eager to adopt cutting-edge technologies, government policies that are aggressively promoting digital health transformation, and a domestic AI medical device industry that is among the most advanced globally. For Canadian digital health companies, Korea represents both a high-potential market and a validation platform for technologies seeking global scale.

This report examines Korea's digital healthcare landscape in 2026, covering the telemedicine regulatory shift, AI diagnostic devices, the government's digital health roadmap, Software as a Medical Device (SaMD) regulation, wearable health devices, and the data infrastructure that underpins the ecosystem.

---

Part 1: Telemedicine — The Regulatory Breakthrough

The December 2025 Legalization

For decades, Korea was one of the few advanced economies where telemedicine was effectively prohibited for most clinical uses. Despite having the technological infrastructure to support remote healthcare delivery, regulatory restrictions limited telemedicine to narrow use cases (remote islands, military installations, and emergency situations). This regulatory gap was a significant structural barrier to digital health innovation.

In December 2025, Korea's National Assembly passed legislation legalizing telemedicine for a substantially broader range of clinical applications. While the law includes safeguards — requirements for initial in-person consultations before remote follow-ups, restrictions on prescribing controlled substances via telemedicine, and data security mandates — it represents a fundamental shift in Korea's healthcare delivery framework.

Market Impact

The telemedicine legalization has catalyzed investment and commercial activity across the digital health sector. The distance health technology sector is projected to reach a valuation of USD $1.3 billion in 2026 as the regulatory framework takes effect and healthcare providers begin implementing telemedicine platforms at scale.

Key implications include:

  • Platform demand: Korean hospitals and clinics need telemedicine technology platforms — video consultation systems, remote monitoring integrations, electronic prescription systems, and patient scheduling tools. This creates immediate market opportunities for companies with proven telemedicine platforms.
  • Remote patient monitoring: Chronic disease management via remote patient monitoring (RPM) becomes commercially viable with telemedicine legalization. Devices that transmit patient data (blood glucose monitors, blood pressure cuffs, pulse oximeters, cardiac monitors) to healthcare providers gain new clinical utility.
  • Rural and elderly care: Korea's aging population, particularly in rural and underserved regions, stands to benefit significantly from expanded telemedicine access, driving sustained demand for scalable remote care solutions.
  • Implications

    Canadian digital health companies should treat Korea as a priority market entry target in 2026. The newly enacted telemedicine framework creates near-term commercial openings in platform licensing, RPM hardware integration, and elder care technology. Early-mover advantage is significant — Korean healthcare institutions are actively sourcing proven foreign platforms to accelerate deployment. Partnerships with domestic Korean health IT distributors or hospital networks are the recommended entry mechanism, given the regulatory nuances around initial in-person consultation requirements and controlled substance prescribing restrictions.